Penny Stocks To Buy [or avoid] After Coronavirus Cases Top 200k
The novel coronavirus has turned the market on its head. World governments are scrambling to figure out what to do next. Current remedies include city-wide shutdowns, school closures, event closures, and even an end to sports for now. The last Democratic debate didn’t even have an audience. But that doesn’t mean it’s a time to be scared. If anything, there are plenty of investors who are more bullish now than ever.
[SPECIAL REPORT] Gold Company In Focus
Depending on the sectors you’re looking at, there could be steep discounts on certain blue-chip stocks. But you also can’t forget the countless penny stocks that are getting gobbled up amid the coronavirus stock rally. Everything from biotech to gold penny stocks are on the table right now. And when it comes to trading penny stocks on platforms like Robinhood, ETrade, TD Ameritrade and others, daily volumes are some of the highest they’ve been all year.
Needless to say, news outlets have made every attempt to keep fear strong in the public eye. But we’re here to tell you that there are more opportunities now than in the last few years to take advantage of the market move. The important part is learning how to trade or learning how to invest in penny stocks and large-caps alike.
Penny Stocks To Buy [or sell]: iBio, Inc.
Since the end of February, iBio Inc. (IBIO) has been one of the cult coronavirus penny stocks to watch. Shares jumped from around $0.30 to highs of $3.40 within a matter of days. While there have been 1 and 2-day rallies in the stock, the overall trend since $3.40 has been down. This week IBIO stock slid below $1 for the first time since it starting making the epic run. But that could have changed after its latest announcement.
On March 18 the company reported big news. iBio announced progress toward developing a vaccine candidate for preventing infection from the SARS-CoV-2 virus. This is the main cause of COVID-19. Just a few weeks ago, iBio created its virus-like particle constructs using its FastPharming System to produce nanoparticles. This also comes just after the company filed 4 provisional patent applications with the U.S. PTO to support its platform.
Dr. Sylvain Marcel, iBio’s VP of Protein Expression Sciences commented, “In addition to our core VLP production capabilities, we are coating VLPs with oligomannose so that their glycosylation profile closely resembles that of naturally occurring SARS-CoV-2 viruses. This may allow for more efficient uptake of the vaccine by human antigen-presenting cells via their mannose receptors.”
Penny Stocks To Buy [or sell]: Vaxart Inc.
Another one of the popular coronavirus penny stocks has been Vaxart Inc. (VXRT). We first began reporting on this company in late January. At the time this was one of the penny stocks that actually had a viable product. Keep in mind that during the early hype-phase of coronavirus, many companies simply made announcements of “plans” to get involved. Vaxart already had an H1 flu tablet vaccine it was working on.
Since then, VXRT stock has managed to reach highs $3.50. This week the company caught another big push of momentum as shares broke back above $3 during the March 18 premarket session. The move came as the company entered into an agreement with Emergent BioSolutions (EBS) to use Vaxart’s services to develop and manufacture Vaxart’s oral vaccine candidate for COVID-19.
Wouter Latour, MD, chief executive officer of Vaxart said, “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavor.”
Penny Stocks to Buy [or sell]: Waitr Holdings
We’ve been watching Waitr Holdings (WTRH) for the better part of the last 3 days. We first came across the company as it was in a transitional period back in November of 2019. This week the company caught steam after reporting its latest round of earnings and offered guidance for the future. Something I thought was important to note was that management cited that it was basically being lazy. In a press release Carl Grimstad, Chairman and CEO of Waitr, said that “distractions resulted in a lack of focus on our customers and operations.”
Looking at the current results, Waitr reported strong growth. It posted a 103% increase in revenue to $43.1 million during the quarter along with a slimmer net loss of $0.28 per share compared to $0.52 per share the same period in 2018. Something else to consider is that delivery stocks are captivating the market right now. That’s in light of the recent quarantine initiatives by cities like San Fransisco and possibly New York City. Other delivery stocks like Blue Apron (APRN) have also benefited from this type of speculation.
- Are These Coronavirus Penny Stocks On Your List Today?
- Penny Stocks Rising On Coronavirus Fears; 5 To Watch
We reported on Blue Apron along with Waitr earlier this week citing that this could be the case and so far that speculative thought process has been correct. While APRN is no longer a penny stock, at the time we brought it up, shares were trading under $4. Today, the former penny stock reached highs of nearly $10 at the opening bell. Will this latest trend in delivery stocks continue as more cities suggest a “remain in place” initiative?